Zerlasiran
Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
For research use only. We do not sell to patients.
- CAS No.: 2646703-64-0
- Formula: C443H594N144O277P40S10
- Molecular Weight:14155.81
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Apolipoprotein A[1]
Zerlasiran (300-600 mg) reduces serum ApoA levels of up to 96-98%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2646703-64-0
-
Appearance Solid
-
Molecular Weight 14155.81
-
Formula C443H594N144O277P40S10
-
Color White to off-white
-
SMILES
[Zerlasiran]
-
Synonyms
SLN360
-
Sequence
RNA, (Am-sp-(2′-deoxy-2′-fluoro)U-sp-Am-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)C-Am-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-Cm-sp-(2′-deoxy-2′-fluoro)C-sp-Gm), complex with RNA (Cm-Gm-Gm-Um-Am-Am-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)G-Am-Cm-Am-Gm-Am-Gm-Um-Um-sp-Am-sp-Um) 5′-[O-[21-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-9,9-bis[12-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-7-mercapto-7-oxido-2,6,8-trioxa-7-phosphadodec-1-yl]-16-mercapto-16-oxido-7,11,15,17-tetraoxa-16-phosphaheneicos-1-yl] hydroxy phosphate] (1:1)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Nissen SE, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2024 May 14;331(18):1534-1543. [Content Brief]
[2]. Fazoli RT, et al. RNA interference therapy in cardiology: will new targets improve therapeutic goals?. Drugs Context. 2024;13:2024-3-1. Published 2024 Aug 20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)